Reid  Leonard net worth and biography

Reid Leonard Biography and Net Worth

Dr. Reid Leonard brings with him a wide array of experience in company formation, drug discovery, business development, and venture capital, having participated in the start-up of several other venture-backed companies: Potenza Therapeutics, Tizona Therapeutics, Trieza Therapeutics, and Twentyeight-Seven, Inc.

Dr. Leonard began his career with Merck & Co., where he served the company for over 25 years. Initially, he carried out discovery research on ion-channel and GPCR targets before moving into business development and licensing. In his later years at Merck, he was instrumental in the formation of the Merck Research Labs Venture Fund. Dr. Leonard retired from Merck as Managing Director of MRL Ventures and Executive Director in Business Development.

Dr. Leonard graduated from Brandeis University with an A.B. in Biology and Psychology, holds a Ph.D. in Biology from Purdue University, and completed a postdoctoral fellowship in molecular pharmacology at Caltech with Profs. Henry Lester and Norman Davidson.

How do I contact Reid Leonard?

The corporate mailing address for Dr. Leonard and other Werewolf Therapeutics executives is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. Werewolf Therapeutics can also be reached via phone at 617-952-0555 and via email at [email protected]. Learn More on Reid Leonard's contact information.

Has Reid Leonard been buying or selling shares of Werewolf Therapeutics?

Reid Leonard has not been actively trading shares of Werewolf Therapeutics during the last quarter. Most recently, Reid Leonard sold 3,000 shares of the business's stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $13.41, for a transaction totalling $40,230.00. Learn More on Reid Leonard's trading history.

Reid Leonard Insider Trading History at Werewolf Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2021Sell3,000$13.41$40,230.00View SEC Filing Icon  
See Full Table

Reid Leonard Buying and Selling Activity at Werewolf Therapeutics

This chart shows Reid Leonard's buying and selling at Werewolf Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Werewolf Therapeutics Company Overview

Werewolf Therapeutics logo
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $6.09
Low: $5.77
High: $6.16

50 Day Range

MA: $6.26
Low: $4.69
High: $7.91

2 Week Range

Now: $6.09
Low: $1.57
High: $8.19

Volume

241,410 shs

Average Volume

179,990 shs

Market Capitalization

$264.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7